This double blind, parallel study compared @entity17013 2 X 25 mcg in each nostril twice daily, with placebo in the prophylaxis of @entity1412 recurrence after surgery. The treatment lasted for 12 months. The study was conducted according to the recommendations of the Declaration of Helsinki, and the @entity1 gave verbal consent to participate. The study was reviewed by the Norwegian Medicines Control Authority. Forty-one @entity1 with first or recurrent polypectomy were enrolled. Thirty-seven @entity1 completed the 12 months' period. Four @entity1 dropped out prematurely for reasons unrelated to the test drug. @entity17013 was significantly superior to placebo in preventing recurrence of @entity1127 during 6 to 12 months' treatment, both with respect to number (p = 0.05) and size (p = 0.03) of @entity1127 . Nasal symptoms of sneezing and stuffiness decreased significantly for @entity17013 treated @entity1 during treatment. In the placebo group, there was a significant increase in stuffiness throughout the year. For runny nose, there was no difference between the treatments. Six @entity17013 @entity1 and 10 placebo @entity1 reported side effects during the one year treatment, transient mild itching being the most common complaint. Three cases of secretion with bloody traces were reported. No @entity1 withdrew for drug related reasons. In this study, @entity17013 was significantly more effective than placebo in preventing recurrence of @entity1412 during one year's treatment after polypectomy.

@entity17013 nasal spray 0.025% in the prophylactic treatment of XXXX after polypectomy. A randomized, double blind, parallel, placebo controlled study.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity1412 :: ('MESH:D011125', 'Disease') :: ['nasal polyposis'] @entity1127 :: ('MESH:D011127', 'Disease') :: ['polyps'] @entity17013 :: ('MESH:C007734', 'Chemical') :: ['flunisolide', 'Flunisolide']
@entity1412 :: (MESH:D011125,Disease) :: ['nasal polyposis']
